A probiotic for improving depression or anxiety and its application

By combining the Bifidobacterium longum subsp. infantis BI03 strain with Lactobacillus acidophilus Lactobacillus acidophilus LA05 strain, the intestinal and serum indicators of mice was adjusted, which significantly improved the symptoms of depression or anxiety and solved the current situation. There is a problem of limited effect of a single strain of probiotics in the art, which achieves more efficient relief of depression and anxiety.

CN118406622BActive Publication Date: 2024-11-01JIANGSU WECARE BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202410875443.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-01
Estimated Expiration
2044-07-02

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve symptoms of depression or anxiety, and the intervention effect of a single strain of probiotics is limited and it is easy to develop resistance.

Method used

The combination of the Bifidobacterium longum subsp. infantis BI03 strain and Lactobacillus acidophilus Lactobacillus acidophilus LA05 strain was used to regulate the intestinal short-chain fatty acids, serotonin, and brain-derived neurotrophic factors in mice. and inflammatory factor levels significantly reduce anxiety and depression-like behaviors.

Benefits of technology

It significantly improves the effect of relieving depression or anxiety, enhances the ability to relieve exercise fatigue, improves serum corticosterone levels, reduces inflammatory factors, and the combination of the two strains is not easy to develop resistance, and the product is highly safe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118406622B_ABST
    Figure CN118406622B_ABST
Patent Text Reader

Abstract

The present invention relates to a probiotic for improving depression or anxiety and application thereof, wherein the strain in the probiotic for improving depression or anxiety comprises Bifidobacterium longum subspecies infantis Bifidobacterium longum subsp.infantis BI03 strain and Lactobacillus acidophilus Lactobacillus acidophilus LA05 strain. The combination of BI03 strain and LA05 strain can cooperate with each other, promote each other, and synergize in improving depression or anxiety, which is manifested in: significantly reducing anxiety and depressive-like behavior in mice; increasing the levels of short-chain fatty acids and neurotransmitters to regulate the brain-gut axis; and restoring the levels of serum corticosterone and inflammatory factors in mice.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to a probiotic for improving depression or anxiety and application thereof. Background Art

[0002] Depression, also known as major depressive disorder, is often accompanied by feelings of guilt and hopelessness, as well as changes in appetite and sleep, leading to impaired daily functioning. Its core symptoms include low mood, lack of joy, low energy, and fatigue, and may also cause sleep and psychomotor disorders, guilt, low self-esteem, and autonomic and gastrointestinal dysfunction. The two-way communication network between the gut and the central nervous system, the brain-gut axis, is closely related to the complex communication of the autonomic, neuroendocrine, and immune systems. Neuroactive substances produced by the gut microbiota play an important role in the brain-gut axis, which in turn affects the function of the central nervous system, including mood regulation and cognitive function.

[0003] Probiotics positively affect the central nervous system by regulating key neurotransmitters involved in depression. Probiotics are a class of live microorganisms that provide health benefits to the host through positive interactions with the endogenous microbiota and intestinal cells. Some lactic acid bacteria and bifidobacteria can alleviate mood disorders and prevent stress-induced changes in the colonic microbiota. These probiotics work through multiple mechanisms, including modulation of the endocrine system, immune pathways, and inflammation to reduce disease symptoms.

[0004] Studies on the effects of probiotics on anxiety and depressive symptoms include endocrine effects related to the hypothalamus-pituitary-adrenal gland, modulation of immune responses, enhancement of epithelial barrier function, neural effects via vagus nerve stimulation, modulation of neurochemicals (such as serotonin, dopamine, γ-aminobutyric acid, and brain-derived neurotrophic factor), and the production of metabolites such as short-chain fatty acids and tryptophan.

[0005] With the in-depth study of the relationship between intestinal microbiota and mental health, it is of great significance to develop a new treatment method for mental illness based on intestinal microbiota. Summary of the invention

[0006] In view of the deficiencies of the prior art, the object of the present invention is to provide a probiotic for improving depression or anxiety and its application.

[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a probiotic for improving depression or anxiety, wherein the strains in the probiotic for improving depression or anxiety include Bifidobacterium longum subsp. infantis BI03 strain with a preservation number of CGMCC No. 24473 and Lactobacillus acidophilus LA05 strain with a preservation number of CGMCC No. 23546.

[0009] The present invention creatively develops a new probiotic compounding method and a new strategy for improving depression or anxiety, namely, compounding and using Bifidobacterium longum subsp. infantis BI03 strain and Lactobacillus acidophilus LA05 strain together. It is found that the two can cooperate with each other, promote each other, and synergize in improving depression or anxiety, which is specifically manifested in: (1) significantly reducing anxiety and depressive-like behavior in mice; (2) having a regulatory effect on short-chain fatty acids in the intestine of mice; (3) significantly increasing the levels of serum 5-hydroxytryptamine and brain-derived neurotrophic factor in mice; (4) significantly increasing the level of serum corticosterone in mice; and (5) significantly increasing the level of serum inflammatory factors in mice.

[0010] When the amount of bacteria used is the same, the combination of the two bacteria significantly improves the effect of relieving sports fatigue compared with the intervention of a single BI03 strain or a single LA05 strain. Therefore, the composite probiotic has a good prospect for preparing drugs for preventing and / or improving depression or anxiety. At the same time, both bacteria are probiotics, the product is highly safe, and it is not easy to develop resistance.

[0011] Preferably, the ratio of the number of viable bacteria of the BI03 strain to the LA05 strain is 1:10-10:1, for example, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, etc. Other specific point values ​​within this numerical range can be selected, and they will not be described here one by one.

[0012] Preferably, the viable counts of the BI03 strain and the LA05 strain are not less than 1×10 8 CFU / mL or 1×10 8 CFU / g, for example 1×10 8 CFU / g (CFU / mL), 2×10 8 CFU / g (CFU / mL), 5×10 8CFU / g (CFU / mL), 8×10 8 CFU / g (CFU / mL), 1×10 9 CFU / g (CFU / mL), 5×10 9 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 1×10 12 CFU / g (CFU / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0013] Preferably, the dosage form of the probiotic includes solution, lyophilized powder, capsule, tablet or granule.

[0014] Preferably, the probiotic is in the form of a freeze-dried powder, which is prepared by the following method:

[0015] The BI03 strain and the LA05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a culture solution; the culture solution is centrifuged to obtain bacterial cells; the bacterial cells are mixed with a lyophilization protective agent and freeze-dried to obtain BI03 lyophilized powder and LA05 lyophilized powder; the BI03 lyophilized powder and the LA05 lyophilized powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent for improving depression or anxiety.

[0016] Preferably, the lyoprotectant is selected from any one or a combination of at least two of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.

[0017] Preferably, the probiotic is in the form of a solution, which is prepared by the following method:

[0018] The BI03 strain and the LA05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged and resuspended with a solvent to obtain a BI03 bacterial suspension and a LA05 bacterial suspension; the BI03 bacterial suspension and the LA05 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.

[0019] Preferably, the probiotics also include functional additives.

[0020] Preferably, the functional auxiliary agent is selected from any one of fructooligosaccharides, galacto-oligosaccharides, xylooligosaccharides, isomaltooligosaccharides, soybean oligosaccharides, polydextrose, α-lactalbumin or lactoferrin, or a combination of at least two thereof.

[0021] In a second aspect, the present invention provides a use of the probiotic for improving depression or anxiety according to the first aspect in the preparation of a medicine for improving depression or anxiety.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention creatively develops a new probiotic compounding method and a new strategy for improving depression or anxiety, that is, Bifidobacterium longum subsp. infantis BI03 and Lactobacillus acidophilus LA05 strains are compounded and used together, and it is found that the two can cooperate with each other, promote each other, and synergize in improving depression or anxiety. When the amount of bacteria is consistent, compared with the intervention method of a single BI03 strain or a single LA05 strain, the compounding of the two bacteria is significantly improved in the effect of relieving depression or anxiety behavior. Therefore, the composite probiotics are used in the preparation of medicines for preventing and / or improving depression or anxiety, which has a good prospect. At the same time, both bacteria are probiotics, the product is highly safe, and it is not easy to produce resistance.

[0024] The classification name of the BI03 strain involved in the present invention is Bifidobacterium longum subsp. Infantis, and the preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration. The preservation time is March 7, 2022, the preservation number is CGMCC No. 24473, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0025] The LA05 strain involved in the present invention is classified and named Lactobacillus acidophilus, and the preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration. The preservation time is October 9, 2021, the preservation number is CGMCC No. 23546, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is the statistical result of the total distance traveled by each group of mice in the central area of ​​the open field test;

[0027] Figure 2 This is a statistical result graph of the time each group of mice stayed in the central area of ​​the open field test;

[0028] Figure 3 It is a statistical result diagram of the percentage of times each group of mice entered the open arm in the elevated maze test;

[0029] Figure 4 This is a statistical result graph of the percentage of time each group of mice spent in the open arm in the elevated maze test;

[0030] Figure 5 This is a statistical result graph of the immobility time of each group of mice in the forced swimming test;

[0031] Figure 6 This is a statistical result graph of the number of climbing times of each group of mice in the forced swimming test;

[0032] Figure 7 This is the statistical result of the immobility time of each group of mice in the dark box;

[0033] Figure 8 It is the statistical result diagram of the number of times each group of mice entered the bright box;

[0034] Fig. 9 This is the statistical result of the intestinal valeric acid content of each group of mice;

[0035] Fig.10 This is a statistical result diagram of the intestinal isovaleric acid content of each group of mice;

[0036] Fig.11 This is the statistical result of the intestinal butyric acid content of each group of mice;

[0037] Fig.12 This is a statistical result diagram of the intestinal isobutyric acid content of each group of mice;

[0038] Fig.13 This is the statistical result of the intestinal propionic acid content of each group of mice;

[0039] Fig.14 This is the statistical result of the intestinal acetic acid content of each group of mice;

[0040] Fig.15 It is the statistical result diagram of 5-HT content in the serum of each group of mice;

[0041] Fig.16 is a statistical result diagram of the content of brain-derived neurotrophic factor in the serum of mice in each group;

[0042] Fig.17 It is the statistical result diagram of the content of ketone in serum cortex of each group of mice;

[0043] Fig.18 is a statistical result diagram of the interleukin-6 content in the serum of each group of mice;

[0044] Fig.19 is a statistical result chart of interleukin-10 content in the serum of mice in each group;

[0045] Fig. 20is a statistical result diagram of the interleukin-1β content in the serum of each group of mice;

[0046] Fig.21 This is a statistical graph of the tumor necrosis factor-α content in the serum of each group of mice. DETAILED DESCRIPTION

[0047] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0048] In the following examples, unless otherwise specified, the reagents and consumables used were purchased from conventional reagent manufacturers in the field; unless otherwise specified, the experimental methods and technical means used were conventional methods and means in the field.

[0049] The BI03 strain involved in the following examples is classified and named as Bifidobacterium longum subsp. infantis, and its deposit number is CGMCC No. 24473.

[0050] The LA05 strain involved in the following examples is classified and named as Lactobacillus acidophilus, and its deposit number is CGMCC No. 23546.

[0051] The peptone, beef extract, glucose, lactose, yeast powder, diammonium hydrogen citrate, K2PO4·3H2O, MgSO4·7H2O, MnSO4, Tween 80 and cysteine ​​hydrochloride involved in the following examples were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0052] The kits involved in the following examples were purchased from Jiangsu ELISA Industrial Co., Ltd.

[0053] The culture medium involved in the following examples is as follows:

[0054] MRS medium (g / L): peptone 10 g / L, beef extract 10 g / L, glucose 15 g / L, lactose 15 g / L, yeast powder 5 g / L, diammonium hydrogen citrate 2 g / L, K2PO4·3H2O 2.6 g / L, MgSO4·7H2O 0.1 g / L, MnSO4 0.05 g / L, Tween 80 1 mL / L, cysteine ​​salt 0.5 g / L.

[0055] The bacterial suspension involved in the following embodiments is as follows: the desired strain is inoculated into MRS liquid culture medium, and cultured at 37°C for 24 hours for activation to obtain an activation solution; the activation solution is inoculated into MRS liquid culture medium at an inoculum amount of 3% (v / v), and cultured at 37°C for 24 hours to obtain a bacterial solution; the bacterial solution is centrifuged at 6000 g for 10 min, and the bacteria are resuspended in PBS to obtain.

[0056] The experimental results were statistically analyzed using graphics software. Compared with the CTL group, ### represents p<0.001, ## represents p<0.01; compared with the model group, *** represents p<0.001, ** represents p<0.01, and * represents p<0.05.

[0057] Example

[0058] This example explores the ability of probiotics to improve depression or anxiety in mice:

[0059] (1) Experimental animals: 6-week-old C57BL / 6 mice (80, purchased from Shanghai Laboratory Animal Center) were housed in a controlled environment with room temperature maintained at 22±2°C and humidity at 55%±5%, following a 12-h light / dark cycle, and free access to food and water. All experimental procedures involving mice were in accordance with the ethical guidelines for the care and use of animals stipulated by the Shanghai Laboratory Animal Care and Experimentation Center.

[0060] (2) Animal grouping: After one week of adaptive feeding as described above, 80 mice were randomly divided into 8 groups (10 mice in each group): control group (CTL group), model group (Dep group), BI03 group (denoted as S1 group), LA05 group (denoted as S2 group), composite bacteria group 1 (BI03+LA05 group, with a live bacteria ratio of 1:1, denoted as S3 group), composite bacteria group 2 (ATCC15697+ATCC4356 group, with a live bacteria ratio of 1:1, denoted as S4 group), composite bacteria group 3 (BI03+LA05 group, with a live bacteria ratio of 1:10, denoted as S5 group), and composite bacteria group 4 (BI03+LA05 group, with a live bacteria ratio of 10:1, denoted as S6 group).

[0061] (3) Animal modeling and intervention methods:

[0062] The model group and probiotic intervention group were subjected to chronic unpredictable mild stimulation (CUMS) for 5 weeks to establish a depression and anxiety mouse model. Chronic unpredictable mild stimulation included the following 10 different stimuli: forced swimming (mice were placed in a 22-cm-deep glass jar filled with 23 ± 2°C water for 10 min and carefully covered with a heavy lid to prevent them from escaping, and then the mice were returned to a clean, dry cage with fresh bedding to avoid chills and colds); restraint (mice were placed in a 50-mL plastic tube, adjusted on the outside with plastic tape so that the animals could not move, and there was a hole at the far end of the tube to facilitate normal breathing); water deprivation (water bottles were removed from the cage within 24 h and returned after the time point was reached); isolation (mice were placed alone in a new cage for 24 h, and then the mice were returned to the cage with their companions); food deprivation (food was removed from the cage for 24 h, and then the food was returned); wet bedding (mice were placed alone in a new cage with 200 mL of water per 100 g of bedding for 24 h). h, the mice were returned to the cage with their companions); no bedding (the mice were placed alone in a new cage without bedding for 24 h, and the animals were returned to the cage with their companions); tilted cage (the cage was tilted at 45° for 24 h, and the cage was returned to normal); tail clamp (the plastic clamp was clamped 2 cm from the end of the tail for 3 minutes each time, 3 times a day, and the animals were returned to the cage with their companions); crowded space (a plastic partition was placed in the cage to reduce the activity area by half, and after 24 h, the partition was removed). In order to avoid the animals' adaptation to specific stimuli, which would affect the accuracy of the experimental results, these stimuli were randomly applied 2 times a day, and the stimulation was randomly applied 6 days a week. In addition, in order to ensure the unpredictability of the experiment, each stimulus was used no more than three times cumulatively during the entire experimental period. This method aims to create a complex and varied stress environment to induce behavioral and physiological responses in mice similar to human depression and anxiety.

[0063] During the whole experimental period, the control group and the model group were fed with conventional feeding, and the probiotic intervention groups were gavaged with probiotic solution at the same time, with a dosage of 5×10 9 CFU / bird / day.

[0064] (4) Behavioral evaluation:

[0065] Behavioral evaluations of all mice began in the seventh week, including open field test, elevated plus maze test, forced swimming test, and light-dark box test.

[0066] (4.1) Open field test: The open field test can be used to evaluate the depressive and anxious behaviors of animals. The specific operation is as follows: the open field consists of a square arena (50 cm × 50 cm) surrounded by continuous opaque walls made of plexiglass. The mouse is placed in the middle of the area facing the wall. The movement activity is monitored for 10 min, and the immobility time of the mouse in the central area and the distance it walks in the central area are measured.

[0067] The results are as follows Figure 1 and Figure 2 As shown, compared with the control group, the total distance walked by the model group in the central area of ​​the open field was significantly reduced, indicating that the mice were in a depressive state, and the time they stayed in the central area of ​​the open field was also significantly reduced, indicating that the mice had a high degree of depression and anxiety. After the intervention of probiotics, the behavioral index tended to normalize, the total distance walked by the mice in the central area of ​​the open field was significantly increased, and the time they stayed was also significantly increased. The combined use of BI03 and LA05 strains had a more prominent effect, which was better than using BI03 or LA05 alone.

[0068] (4.2) Elevated plus maze test: The elevated plus maze test can be used to evaluate animal depression and anxiety behaviors. The specific operation is as follows: the mice are placed in the central area of ​​the maze, facing the open arms. The animals are allowed to move freely for 6 min, and their behavior is recorded by a video tracking system. The entry into the light arm (open arm) and the dark arm and the time spent in the light arm are recorded.

[0069] The results are as follows Figure 3 and Figure 4 As shown, compared with the control group, the percentage of open arm entries and the open arm residence time of mice in the model group were significantly reduced, which suggested increased hesitation and anxiety behavior. After the intervention of probiotics, the behavioral index tended to normalize, and the effect of the combination of BI03 and LA05 strains was more prominent, which was better than using BI03 or LA05 alone.

[0070] (4.3) Forced swimming test: The forced swimming test can be used to evaluate the depressive behavior of animals. The specific operation is as follows: use a 30 cm glass tank with 23-25℃ water. On the first day, all mice were forced to swim for 15 minutes for training; on the second day, the mice were placed in the same environment for 6 minutes. A video tracking system was used to monitor motor activity, and software was used to calculate the immobility time and the number of climbs of each animal during the test. Immobility refers to the animal's lack of other behavior except for active upward movement to avoid submersion in water. Climbing refers to the animal's behavior of using its front paws to climb up along the inner wall of the swimming pool or the vigorous movement of its front paws to continuously break through the water surface and slap.

[0071] The results are as follows Figure 5 and Figure 6 As shown, compared with the control group, the immobility time of mice in the model group in the forced swimming test was significantly increased and the climbing times were significantly reduced, which reflected a higher level of despair behavior, a typical manifestation of depression. After the intervention of probiotics, the behavioral index tended to normalize, and the effect of the combination of BI03 and LA05 strains was more prominent, which was better than using BI03 or LA05 alone.

[0072] (4.4) Light-dark box test: It can be used to evaluate the depressive behavior of animals. The specific operation is as follows: The device consists of a box (50 cm × 21 cm × 25 cm), which is divided into a light box and a dark box (half each). The mouse is placed in the dark box, initially facing the door of the light box. The real-time monitoring system records the activity of the mouse for 5 minutes, and calculates the immobility time of the mouse in the dark box and the number of times it enters the light box.

[0073] The results are as follows Figure 7 and Figure 8 As shown, compared with the control group, the model group's immobility time in the dark box was significantly increased, and the number of times entering the light box was significantly reduced, which is a typical manifestation of depression. After the intervention of probiotics, the mice's immobility time in the dark box was significantly reduced, and the number of times entering the light box was significantly increased, with obvious exploratory behavior. This reaction is psychologically considered to be a better emotional state and stress adaptation ability. The combined use of BI03 and LA05 strains has a more prominent effect, which is better than using BI03 or LA05 alone.

[0074] (5) Detection of short-chain fatty acid content in mouse intestine:

[0075] After the behavioral test, the mice were euthanized and the cecal contents of the mice were collected. Weigh the appropriate amount of dried cecal contents, add 500 μL saturated NaCl, shake evenly, add 40 μL 10% sulfuric acid, shake evenly; add 1 mL ether, shake evenly; centrifuge at 18000 g, 4℃ for 15 min, take the supernatant to a 2 mL EP tube, add 0.25 g anhydrous sodium sulfate. Centrifuge at 18000 g, 4℃ for 15 min. Take 500 μL of the supernatant to a gas phase vial, and detect the contents of valeric acid, isovaleric acid, butyric acid, isobutyric acid, propionic acid, and acetic acid by GC-MS with selected ion scanning.

[0076] The results are as follows Figure 9-14As shown, compared with the control group, the contents of valeric acid, isovaleric acid, butyric acid, isobutyric acid, propionic acid and acetic acid in the model group mice were significantly reduced. After the intervention of probiotics, the content of short-chain fatty acids in the depressed mice was significantly regulated, and the contents of valeric acid, isovaleric acid, butyric acid, isobutyric acid, propionic acid and acetic acid were significantly increased, indicating that the combined probiotic intervention can effectively alleviate the symptoms of depression and anxiety, and the effect of the combined use of BI03 and LA05 strains is more prominent, which is better than using BI03 alone or LA05 alone.

[0077] (6) Determination of serum 5-HT and BDNF levels in mice:

[0078] After the behavioral test, the mice were euthanized, and their blood was collected and centrifuged at 1500 g for 15 min to obtain serum. The levels of 5-HT and BDNF in the serum were detected using a kit.

[0079] The results are as follows Fig.15 and Fig.16 As shown, compared with the control group, the levels of serotonin and brain-derived neurotrophic factor in the serum of the model group mice were significantly reduced. After the intervention of probiotics, this symptom was significantly alleviated, and the levels of serotonin and brain-derived neurotrophic factor in the serum of the mice gradually returned to normal levels, showing good anti-depression and anxiety potential. The combined use of BI03 and LA05 strains had a more prominent effect, which was better than using BI03 or LA05 alone.

[0080] (7) Determination of serum corticosterone levels in mice:

[0081] After the behavioral test, the mice were euthanized, and their blood was collected and centrifuged at 1500 g for 15 min to obtain serum. The level of corticosterone in the serum was detected using a kit.

[0082] The results are as follows Fig.17 As shown, compared with the control group, the corticosterone content in the serum of the mice in the model group was significantly increased. After the intervention of probiotics, the corticosterone content in the serum of the mice was significantly reduced and gradually returned to normal levels, showing good anti-depression and anxiety effects. The combined use of BI03 and LA05 strains had a more prominent effect, which was better than using BI03 or LA05 alone.

[0083] (8) Determination of serum inflammatory factor levels in mice:

[0084] After the behavioral test, the mice were euthanized, and their blood was collected and centrifuged at 1500 g for 15 min to obtain serum. The levels of interleukin-6, interleukin-10, interleukin-1β, and tumor necrosis factor-α in the serum were detected using kits.

[0085] The results are as follows Figure 18-Figure 21 As shown in the figure, compared with the control group, the levels of interleukin-6, interleukin-10, interleukin-1β and tumor necrosis factor-α in the serum of the model group mice increased significantly. After the intervention of probiotics, this symptom was significantly alleviated. The levels of interleukin-6, interleukin-10, interleukin-1β and tumor necrosis factor-α in the serum of mice decreased significantly and gradually returned to normal levels, and the inflammation of mice was relieved. This reflects that the compound probiotics have a multi-level and complex impact on immune regulation when intervening in depression, further confirming the therapeutic potential of the compound probiotics in relieving depression and anxiety symptoms. The combined use of BI03 and LA05 strains has a more prominent effect, which is better than using BI03 or LA05 alone.

[0086] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0087] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0088] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A probiotic for improving depression or anxiety, It is characterized in that The strain in the probiotic for improving depression or anxiety is Bifidobacterium longum subspecies infantis with a deposit number of CGMCC No. 24473. Bifidobacterium longum subsp. infantis BI03 strain and Lactobacillus acidophilus with a deposit number of CGMCC No. 23546 Lactobacillus acidophilus LA05 strain composition; the ratio of the number of viable bacteria of the BI03 strain to the LA05 strain is 1:10-10:1; the number of viable bacteria of the BI03 strain and the LA05 strain is not less than 1×10 8 CFU / mL or 1×10 8 CFU / g.

2. The probiotic for improving depression or anxiety according to claim 1, It is characterized in that The dosage form of the probiotics includes solution, lyophilized powder, capsule, tablet or granule.

3. The probiotic for improving depression or anxiety according to claim 2, It is characterized in that The dosage form of the probiotic is a freeze-dried powder, which is prepared by the following method: The BI03 strain and the LA05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a culture solution; the culture solution is centrifuged to obtain bacterial cells; the bacterial cells are mixed with a lyophilization protective agent and freeze-dried to obtain BI03 lyophilized powder and LA05 lyophilized powder; the BI03 lyophilized powder and the LA05 lyophilized powder are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent for improving depression or anxiety.

4. The probiotic for improving depression or anxiety according to claim 3, It is characterized in that The lyoprotectant is selected from any one or a combination of at least two of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.

5. The probiotic for improving depression or anxiety according to claim 2, It is characterized in that The dosage form of the probiotic is a solution, which is prepared by the following method: The BI03 strain and the LA05 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged and resuspended with a solvent to obtain a BI03 bacterial suspension and a LA05 bacterial suspension; the BI03 bacterial suspension and the LA05 bacterial suspension are mixed according to the ratio of the number of live bacteria to obtain the probiotic agent.

6. The probiotic for improving depression or anxiety according to claim 1, It is characterized in that The probiotics also include functional additives.

7. The probiotic for improving depression or anxiety according to claim 6, It is characterized in that The functional auxiliary agent is selected from any one of fructooligosaccharides, galacto-oligosaccharides, xylooligosaccharides, isomaltooligosaccharides, soybean oligosaccharides, polydextrose, α-lactalbumin or lactoferrin, or a combination of at least two thereof.

8. Use of the probiotic for improving depression or anxiety according to any one of claims 1 to 7 in the preparation of a medicine for improving depression or anxiety.

Citation Information

Patent Citations

  • Lactobacillus acidophilus capable of resisting helicobacter pylori infection as well as culture method and application of lactobacillus acidophilus

    CN114525231A

  • Composition for relieving emotional fluctuation

    CN115177644A

  • Bifidobacterium longum subsp.infantis for improving Parkinson's disease and application thereof

    CN116751727A

  • Probiotic composition beneficial to emotion regulation, probiotic particles, preparation method and application

    CN117815288A

Cited By

  • Bifidobacterium composition for relieving emotional disorder caused by constipation and application of bifidobacterium composition

    CN120604850A